Polymeric
excipients are crucial ingredients in modern pills, increasing
the therapeutic bioavailability, safety, stability, and accessibility
of lifesaving products to combat diseases in developed and developing
countries worldwide. Because many early-pipeline drugs are clinically
intractable due to hydrophobicity and crystallinity, new solubilizing
excipients can reposition successful and even failed compounds to
more effective and inexpensive oral formulations. With assistance
from high-throughput controlled polymerization and screening tools,
we employed a strategic, molecular evolution approach to systematically
modulate designer excipients based on the cyclic imide chemical groups
of an important (yet relatively insoluble) drug phenytoin. In these
acrylamide- and methacrylate-containing polymers, a synthon approach
was employed: one monomer served as a precipitation inhibitor for
phenytoin recrystallization, while the comonomer provided hydrophilicity.
Systems that maintained drug supersaturation in amorphous solid dispersions
were identified with molecular-level understanding of noncovalent
interactions using NOESY and DOSY NMR spectroscopy. Poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide) (poly(NIPAm-co-DMA))
at 70 mol % NIPAm exhibited the highest drug solubilization, in which
phenytoin associated with inhibiting NIPAm units only with lowered
diffusivity in solution. In vitro dissolution tests of select spray-dried
dispersions corroborated the screening trends between polymer chemical
composition and solubilization performance, where the best NIPAm/DMA
polymer elevated the mean area-under-the-dissolution-curve by 21 times
its crystalline state at 10 wt % drug loading. When administered to
rats for pharmacokinetic evaluation, the same leading poly(NIPAm-co-DMA) formulation tripled the oral bioavailability compared
to a leading commercial excipient, HPMCAS, and translated to a remarkable
23-fold improvement over crystalline phenytoin.